You want the numbers first. Before you hand a panel to any service, it's worth understanding the difference between a platform built to *interpret* your data and one built to *transact* on it.

Two different products wearing similar ads

Most telehealth ads look alike: clean type, a doctor logo, a button. Underneath, they fall into two very different categories.

The first is a single-script visit. You select a product, fill out a questionnaire, a provider reviews it asynchronously, and — if appropriate — a prescription is issued. It's fast, and for some narrow needs it's a reasonable fit. But the unit of work is the script, not your physiology.

The second is coordinated care: labs are drawn first, an independent provider reviews the full panel with context, and any decision — including the decision to do nothing — comes after the data exists. The unit of work is your baseline.

If your goal is a complete picture you can track year over year, those are not interchangeable. The tell isn't the marketing; it's the *sequence*. Does the panel come before the recommendation, or after the checkout?

What a real baseline actually contains

A seven-minute physical with one cholesterol line is not a baseline. A defensible longevity panel typically goes wider, because single markers hide risk that combinations reveal.

A few examples worth knowing the reasoning behind:

  • ApoB and a standard lipid panel. LDL cholesterol is a concentration; apolipoprotein B is a *count* of the atherogenic particles that actually deposit in artery walls. Major guidance now recognizes apoB and non-HDL cholesterol as useful measures of risk that LDL-C alone can miss, especially in people with metabolic issues [1][2].
  • HbA1c and fasting glucose. HbA1c reflects roughly three months of average glucose; the American Diabetes Association uses defined thresholds to categorize prediabetes and diabetes [3]. A wearable can suggest a pattern, but it cannot return a diagnostic number.
  • hs-CRP. A marker of low-grade inflammation that adds context to cardiovascular risk discussions [2].
  • Total and free testosterone (for men with symptoms). The Endocrine Society is explicit that a diagnosis of hypogonadism should rest on consistent symptoms *plus* unequivocally low morning testosterone confirmed on repeat testing — not a single value or a symptom checklist alone [4].

The point isn't to order everything. It's that interpretation depends on seeing markers *together*. A provider reading apoB, HbA1c, and hs-CRP in the same sitting can reason about your metabolic and cardiovascular picture in a way no one-line result allows.

Markers a wider baseline can read together
particle countApoBatherogenic particles, not just LDL concentration [1]
~3 monthsHbA1caverage glucose over time [3]
inflammationhs-CRPadds cardiovascular context [2]
repeat AM testTestosteroneconfirm low value before diagnosis [4]

Source: [1] 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol, [2] 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, [3] ADA Standards of Care: Classification and Diagnosis of Diabetes, [4] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline

ADA HbA1c categories
Normal ≤5.7Prediabetes ≤6.5Diabetes range ≤8

% HbA1c · marker = Prediabetes threshold

Source: [3] ADA Standards of Care: Classification and Diagnosis of Diabetes

Review depth: where the two models diverge

This is the difference a skeptical reader should weigh hardest.

In a single-script flow, the provider's review is scoped to one question: is this person an appropriate candidate for this product? That's a legitimate task, but it is narrow by design.

In coordinated care, the review starts from your numbers and works outward. The questions become: what does this panel show, what's worth watching, what — if anything — is worth acting on, and what should be re-checked and when. That's the conversation Daniel's annual physical skipped and Marcus's wearable can't have.

Neither model can promise a prescription. A prescription is always a clinical decision made by an independent licensed provider, and "the data doesn't support it" is a valid — and useful — outcome.

The sequence coordinated care follows
1Baseline labsnumbers exist before any recommendation
2Provider reviewindependent provider reads the full panel with you
3Decisionincluding 'no intervention'; never guaranteed
4Re-test & trendcompare year over year

Source: [4] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [5] HHS: Your Rights Under HIPAA

Follow-up is the part the ad doesn't show

A baseline is only worth something if you can compare it to the *next* one. Year-over-year trend data is where small drifts — a rising HbA1c still inside "normal," a creeping apoB — show up before they become events. A single-script visit has no structural reason to retain or re-measure your data; the transaction ends at the script. Coordinated care is built around the second and third data points.

When you compare tabs, ask each service plainly: Do you re-test? On what cadence? Can I export my own results? Who reviews the trend, and will they talk to me about it?

Data ownership: read this before you upload anything

Lab results are protected health information. When care is delivered by licensed providers, that information is generally governed by HIPAA, which sets federal standards for how your health data is used and disclosed and gives you a right to access your own records [5]. The U.S. rules on information blocking also reinforce your right to your electronic health information without unreasonable interference [6].

Practical questions to ask before sharing a panel:

  • Who is the covered entity — the provider group, or the marketing platform?
  • Can I download my full results in a portable format?
  • Is my data used for anything beyond my care?
  • If I cancel, what happens to my records?

A service that answers these crisply is showing you its architecture. One that gets vague is answering the question a different way.

A short checklist for the comparison tab

  • Sequence: Panel before recommendation, or product before panel?
  • Breadth: Does the panel go beyond a basic lipid line (apoB, HbA1c, hs-CRP, hormones where indicated)?
  • Review: Is there a real conversation about *your* numbers, not just product eligibility?
  • Follow-up: Is re-testing and trend review part of the model?
  • Ownership: Can you export your data, and who controls it?
  • Honesty: Is "no intervention needed" a possible, stated outcome?

If a service fails the first and last items, it's likely a storefront with a doctor logo. If it passes both, it's at least built for the thing you actually want.

*This article is educational and not medical advice. Lab interpretation and any treatment decision belong to an independent licensed provider who reviews your individual results.*

Where Velri fits

Velri is a technology and coordination company — not a medical practice. We help coordinate the parts: lab work through partnered facilities, a visit with an independent, licensed provider who reviews your results with you, and — *only if that provider determines it's appropriate* — fulfillment through an independent, licensed pharmacy. We don't provide medical care, we don't decide who gets a prescription, and a prescription is never guaranteed.

If certain compounded medications ever come up in your visit: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.

The model is deliberately built around the sequence you'd want: your numbers first, a real review second, and any decision last.